Cantor Fitzgerald Brokers Lower Earnings Estimates for RARE

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Equities researchers at Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of Ultragenyx Pharmaceutical in a research report issued on Wednesday, May 7th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will post earnings of ($5.08) per share for the year, down from their previous estimate of ($4.99). Cantor Fitzgerald currently has a “Overweight” rating and a $118.00 price target on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The company had revenue of $139.29 million for the quarter, compared to analyst estimates of $145.98 million. During the same period in the prior year, the company posted ($2.03) EPS. The business’s revenue was up 28.0% on a year-over-year basis.

Other research analysts have also issued research reports about the stock. Canaccord Genuity Group boosted their target price on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th. Wedbush restated a “neutral” rating and set a $48.00 target price (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. JPMorgan Chase & Co. lifted their price target on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an “overweight” rating in a research report on Thursday, March 27th. HC Wainwright reiterated a “buy” rating and set a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Finally, Morgan Stanley raised their price target on shares of Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an “overweight” rating in a research report on Friday. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $90.93.

Ultragenyx Pharmaceutical Stock Down 2.3 %

NASDAQ:RARE opened at $35.16 on Friday. The company’s 50 day moving average is $36.77 and its 200-day moving average is $42.32. Ultragenyx Pharmaceutical has a 12 month low of $29.59 and a 12 month high of $60.37. The firm has a market cap of $3.30 billion, a price-to-earnings ratio of -5.55 and a beta of 0.34.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 25,000 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $42.48, for a total value of $1,062,000.00. Following the completion of the transaction, the chief executive officer now owns 2,158,985 shares in the company, valued at approximately $91,713,682.80. The trade was a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider John Richard Pinion sold 14,439 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $607,881.90. Following the sale, the insider now owns 107,766 shares in the company, valued at approximately $4,536,948.60. This trade represents a 11.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 125,405 shares of company stock worth $5,285,169 over the last three months. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB bought a new stake in shares of Ultragenyx Pharmaceutical during the third quarter valued at approximately $83,000. Nordea Investment Management AB raised its position in shares of Ultragenyx Pharmaceutical by 8.9% during the fourth quarter. Nordea Investment Management AB now owns 39,673 shares of the biopharmaceutical company’s stock worth $1,658,000 after acquiring an additional 3,246 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Ultragenyx Pharmaceutical by 1.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock valued at $928,000 after acquiring an additional 294 shares during the last quarter. KBC Group NV increased its position in Ultragenyx Pharmaceutical by 2,275.8% in the fourth quarter. KBC Group NV now owns 61,010 shares of the biopharmaceutical company’s stock worth $2,567,000 after purchasing an additional 58,442 shares during the period. Finally, R Squared Ltd bought a new stake in Ultragenyx Pharmaceutical during the 4th quarter worth about $103,000. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.